Veru (VERU) Q4 2025 earnings summary

Executive summary

• Positive Phase 2b QUALITY trial for enobosarm combined with GLP-1 RA showed 100% lean mass preservation and enhanced fat loss in older obese patients, with regulatory clarity from the FDA for further development.

• Focused on late-stage development of enobosarm and sabizabulin for cardiometabolic and inflammatory diseases, emphasizing obesity and muscle preservation in combination with GLP-1 receptor agonists.

• Planned initiation of Phase 2b PLATEAU clinical study in Q1 2026, targeting older patients (age ≥65, BMI ≥35) to address weight loss plateau seen with GLP-1 RA monotherapy.

• Divested legacy FC2 Female Condom business to focus exclusively on drug development.

• Completed public offering post-fiscal year end, raising $23.4 million in net proceeds.

Financial highlights

• Fiscal 2025 net loss from continuing operations was $15.7 million ($1.07 per diluted share), improved from $35.3 million loss in prior year.

• Research and development expenses increased to $15.6 million, driven by obesity clinical study expenses.

• General and administrative expenses decreased to $19.9 million from $24.6 million year-over-year.

• Cash, cash equivalents, and restricted cash were $15.8 million as of September 30, 2025, with an additional $23.4 million raised in a public offering in October 2025.

• Net loss from discontinued operations (FC2 business) was $7 million, including a $4.1 million loss on sale.

Outlook and guidance

• Phase 2b PLATEAU clinical trial to begin in Q1 2026, targeting obese patients (BMI ≥35, age ≥65) initiating GLP-1 therapy, with interim analysis at 36 weeks (Q1 2027) to assess changes in lean and fat mass; primary endpoint is % change in total body weight at 72 weeks.

• FDA guidance supports incremental weight loss as an approvable primary endpoint, with preservation of physical function and body composition as key secondary endpoints.

• Current cash position expected to fund operations through the interim analysis of the PLATEAU study.